Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
1. Medicare to cover GLP-1 obesity drugs starting mid-2026. 2. Eli Lilly and Novo Nordisk will lower prices under new agreement. 3. Deals could allow 40 million new patients access to GLP-1s. 4. Pilot program for Medicare coverage launches in spring 2026. 5. Lower out-of-pocket costs may enhance drug accessibility significantly.